CLARIX CORD 1K
CLARIX CORD 1K
- Unmatched thickness for superior handling
CLARIX® CORD 1K cryopreserved umbilical cord allograft as an adjunct to surgery supports superior outcomes1-2 - No specific orientation
For worry-free application during surgery - Easy to place at the surgical site
Requires minimal or no additional operating room time
Robot Assisted Radical Prostatectomy
CASE REPORT BY MUTAHAR AHMED, M.D. NJ CENTER FOR PROSTATE CANCER AND UROLOGY MAYWOOD, NJ
CLINICAL HISTORY: 52-year-old healthy male with no other medical history was found to have elevated PSA of 4.5. A multiple core biopsy of the prostate showed evidence of high grade cancer with Gleason 7 (4+3) score, while the metastatic work-up came back negative. Patient had no voiding issues, and has excellent erectile function with SHIM score of 24/25. There are many different treatment options for prostate cancer, however…
FOR MEDICAL PROFESSIONALS ONLY: Fill out the form to download the CLARIX informational brochure.
Helps Support a Regenerative Healing Environment
Helps support a regenerative healing environment and the restoration of urinary and sexual function after radical prostatectomy.2-3
- Supports a pro-regenerative environment
- Supports expedited wound healing and functional recovery3
- Reduces adhesion formation
- Helps restore tissue function
- Cryopreserved amniotic membrane has also been recognized by the the FDA as reducing inflammation and scarring on the ocular surface4
THE SCIENCE BEHIND FASTER RECOVERY
For over 30 years, our pioneering scientists have focused on understanding the regenerative features of human birth tissue—ultimately identifying HC-HA/PTX3 as a key orchestrator in regenerative healing4 in the human fetal environment.
Our CRYOTEK® Cryopreservation Process has been shown to preserve the structural and functional integrity of the native tissue significantly better than heat dehydration, thereby delivering the benefits of the natural tissue to the wound.4,6
Dr. Ravi Munver (Hackensack University Medical Center, Hackensack, New Jersey) showed application of UC allograft during nerve-sparing (NS) robotic-assisted laparoscopic radical prostastectomy (RALP) improved recovery of potency. At 6 months, 75% of patients in the UC group (n=16) were potent compared to 57% in the control group (n=16) (p<0.001). At this 12 months, this trend continued with 88% vs 69% potency (p<0.001).3
Dr. Mutahar Ahmed (NJ Center for Prostate Cancer and Urology, Maywood, NJ> reported 65% of patients (n=100) receiving UC were continent at 4 weeks compared to 44% of control patients (n=100) (p=0.018), 83% vs 70% at 3 months (p=0.03) and 97% vs 87% at 12 months (p=0.009).3
Access the TissueTech Physician Portal
The Physician Portal includes a variety of valuable educational resources to help you become more comfortable with our game-changing products so you can readily apply them in your clinical practice. Learn more about our advanced platform technology and how it’s utilized in the most complex medical conditions, as well as the vast body of scientific and clinical research which backs its use.
Join the Amniox DocMatter Community
Peer-to-Peer Clinical Discussion Around CLARIX
DocMatter is a private online professional community for physicians, designed to facilitate peer-to-peer discussions relating to CLARIX – including best practices, interesting and challenging cases, as well as innovative treatment approaches.
Contact Us
Note: CLARIX CORD 1K is a cryopreserved umbilical cord product. For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert. Copyright ©2019 TissueTech Incorporated. All rights reserved. TissueTech and CLARIX CORD 1K are registered trademarks of TissueTech, Inc.
